CAN
NMTR

Cetera Advisor Networks’s 9 Meters Biopharma NMTR Stock Holding History

Cetera Advisor Networks’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-500
Closed -$11K – 2070
2021
Q2 		$11K Buy
+500
New +$12.3K ﹤0.01% 1885

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Cetera Advisor Networks's NMTR Position: Q3 2021 in Review

Cetera Advisor Networks sold out of 9 Meters Biopharma (NMTR) in Q3 2021, closing a stake of 500 shares — an estimated $11K sold.

Cetera Advisor Networks first reported a position in NMTR in Q2 2021 and held it in 1 quarter. The position peaked at $11K in Q2 2021. 105 funds tracked by Wall St. Rank hold NMTR as of Q3 2021.

  • Cetera Advisor Networks reported no remaining 9 Meters Biopharma position as of Q3 2021 after selling out during the quarter.
  • Cetera Advisor Networks sold 500 9 Meters Biopharma shares in Q3 2021, an estimated $11K.
  • Cetera Advisor Networks first reported a position in 9 Meters Biopharma in Q2 2021 and held it in 1 quarter.
  • Cetera Advisor Networks's 9 Meters Biopharma position peaked at $11K in Q2 2021.
  • 105 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q3 2021.

Based on Cetera Advisor Networks's 13F filing for Q3 2021, filed 16 Nov 2021.